Tirzepatide 10mg

Starter Dual GIP/GLP-1 Agonist for Initial Research

Tirzepatide 10mg is an accessible starter-level dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist designed for initial metabolic research. This 10mg supply provides researchers with the most economical entry point to explore groundbreaking dual incretin mechanisms and next-generation metabolic science.

Why Researchers Choose Tirzepatide 10mg:

• Most Affordable Entry: 10mg provides the most economical way to begin tirzepatide research
• Dual Mechanism Innovation: Access to first-in-class dual GIP/GLP-1 receptor agonist technology
• Superior to Single Agonists: Enhanced efficacy compared to GLP-1-only peptides like semaglutide
• Perfect for Testing: Ideal quantity for initial experiments and protocol validation
• No Commitment: Explore tirzepatide's potential without large financial investment
• Same High Quality: Pharmaceutical-grade purity (≥98%) as larger formats
• Quick Start Research: Begin investigating dual incretin pathways immediately
• Proof-of-Concept: Perfect for generating preliminary data and feasibility studies

Ideal Research Applications:

Perfect for laboratories initiating tirzepatide research, conducting preliminary studies, or exploring dual incretin mechanisms for the first time. Tirzepatide 10mg is particularly valuable for researchers who:

• Are new to dual GIP/GLP-1 receptor agonist research
• Want to compare tirzepatide with single-receptor agonists (like semaglutide)
• Need to validate experimental protocols before larger investments
• Are conducting focused, hypothesis-driven experiments
• Want to explore why tirzepatide outperforms GLP-1-only agonists
• Need preliminary data for grant applications or funding proposals
• Are working within strict budget constraints
• Want to test tirzepatide's unique dual mechanism firsthand

Key Research Areas:

• Dual incretin receptor activation vs. single-receptor mechanisms
• Synergistic effects of GIP and GLP-1 co-activation
• Body weight regulation and appetite suppression
• Glucose-dependent insulin secretion pathways
• Comparative efficacy with semaglutide and other GLP-1 agonists
• Metabolic rate and energy expenditure
• Beta-cell function and glucose homeostasis
• Lipid metabolism and cardiovascular benefits
• Dose-response relationship studies

Technical Specifications:

• Quantity: 10mg (starter research supply)
• Type: Dual GIP/GLP-1 receptor agonist
• Structure: 39 amino acid synthetic peptide
• Form: Lyophilized powder for reconstitution
• Purity: ≥98% (HPLC verified)
• Molecular Weight: ~4813 Da
• Storage: Store at 2-8°C before reconstitution; -20°C after reconstitution
• Solubility: Reconstitute with bacteriostatic water
• Stability: Enhanced stability profile with C20 fatty acid modification
• Quality: Pharmaceutical-grade for reliable results

Research Advantages:

Tirzepatide represents a paradigm shift in incretin-based research, combining GIP and GLP-1 receptor activation to produce superior metabolic outcomes. The 10mg supply provides researchers with an accessible entry point to this revolutionary peptide technology.

Unique Dual Mechanism: Unlike single-receptor agonists such as semaglutide or liraglutide, Tirzepatide activates both GIP and GLP-1 receptors simultaneously. This dual activation creates synergistic effects that exceed the sum of individual receptor stimulation, leading to enhanced insulin secretion, reduced glucagon levels, delayed gastric emptying, and superior appetite suppression.

Clinical Breakthrough: Tirzepatide has demonstrated unprecedented efficacy in clinical trials, achieving up to 22.5% body weight reduction—significantly more than semaglutide's 15-17% weight loss. This superior performance makes tirzepatide a critical tool for understanding next-generation metabolic therapeutics.

Why Tirzepatide Outperforms GLP-1 Agonists: The addition of GIP receptor activation provides unique benefits including improved insulin sensitivity, enhanced lipid metabolism, and potentially greater effects on energy expenditure. Research suggests the GIP component contributes to tirzepatide's superior weight loss and metabolic outcomes.

Perfect for Initial Studies: The 10mg quantity is ideal for researchers who want to explore tirzepatide's unique mechanisms and validate their experimental approaches. It provides sufficient material for initial experiments, protocol optimization, and preliminary data collection.

Cost-Effective Exploration: For laboratories new to tirzepatide research or working with limited budgets, the 10mg format offers the most accessible entry point while maintaining pharmaceutical-grade quality standards.

Research Efficiency: With 10mg, researchers can conduct focused experiments, test specific hypotheses, and gather meaningful data to determine if tirzepatide is the right peptide for their research program before committing to larger quantities.

Important Disclaimer: This product is sold exclusively for research and laboratory purposes. Not intended for human consumption, therapeutic use, weight loss applications, or veterinary use. For in vitro and animal research only.

*Price per vial.
*This product is in powder form and is not reconstituted.
*For research purposes only.
*Tested at 99% purity.
*Free shipping.
*All sales final.